Skip to main content
. Author manuscript; available in PMC: 2011 Apr 15.
Published in final edited form as: Cancer. 2010 Apr 15;116(8):2020–2030. doi: 10.1002/cncr.24897

Table 3.

Longitudinal analysis of pulmonary function in 89 survivors of childhood hematologic malignancies who received allogeneic HSCT

Tests Factors P value Estimates of slope
Obstructive values
 FEV1/FVC Male 0.026 −2.6554
Recipient age (year) 0.0004 −0.5444
Years from HSCT 0.0001 −0.2482
 FEV1 Respiratory event (<1yr after HSCT) 0.003 −11.4091
 FEF25%–75% Recipient age (year) < 0.0001 −2.4812
Years from HSCT < 0.0001 −1.909
Air trapping values
 RV Female 0.0039 −18.7051
Years from HSCT < 0.0001 −3.369
 RV/TLC Respiratory event (<1yr after HSCT) 0.014 4.1278
Recipient age (year) < 0.0001 0.6059
Years from HSCT 0.0039 −0.2847
 FRC Years from HSCT < 0.0001 −2.347
Restrictive values
 FVC Respiratory event (<1yr after HSCT) 0.003 −11.7654
Female 0.015 −6.9235
 TLC Female 0.033 −6.6557
Years from HSCT < 0.0001 −1.179
Diffusion values
 DLCOcorr Years from HSCT < 0.0001 −2.544
Recipient age (year) < 0.0001 −2.015

DLCOcorr indicates diffusion capacity corrected for hemoglobin; FEF25–75%, forced mid-expiratory flow; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FRC, functional residual capacity; GVHD, graft versus host disease; HSCT, hematopoietic stem cell transplantation; RV, residual volume; TLC, total lung capacity